

Why carry out this study?

- Reduction in intraocular pressure (IOP) can prevent vision loss in primary open angle glaucoma (POAG), and may also be an important strategy in the management of normal tension glaucoma (NTG).
- This study evaluated the effect of once daily latanoprostene bunod (LBN), a novel nitric-oxide (NO)-donating prostaglandin F₂ α receptor agonist, on 24-hour IOP in healthy male Japanese subjects.

What was learned from the study?

- LBN given once daily for 14 days reduced IOP by a mean (SD) of 3.6 (0.8) mm Hg from baseline in healthy Japanese subjects, with peak IOP reduction (30%) observed 12 hours after instillation.
- The findings from this and prior research suggest the potential for once daily LBN to produce clinically meaningful IOP reductions in patients with POAG and possibly NTG.

This summary slide represents the opinions of the authors. Sponsorship for this study was funded by Bausch & Lomb, Inc. Medical writing assistance for this study was provided by Kurt Brubaker, Bridge Over Brook (Medford, OR) and funded by Bausch & Lomb, Inc. For a full list of acknowledgments and disclosures for all authors of this article, please see the full text online. © The Author(s) 2015. Creative Commons Attribution Noncommercial License (CC BY-NC).